Using High-Resolution MS to Identify Antibody Light/Heavy Chains and Isoforms
-
Whether C-terminal lysine is present.
-
Whether truncation or partial degradation has occurred.
-
Whether additional modifications, such as oxidation or deamidation, are present.
Monoclonal antibodies (monoclonal antibodies, mAbs) represent one of the most important classes of biopharmaceutical molecules, and their structural integrity directly determines efficacy, safety, and batch-to-batch consistency. In antibody quality analysis, assessment of light-chain (Light chain, LC) and heavy-chain (Heavy chain, HC) integrity, together with the identification of isoforms, represents an important component of critical quality attribute (CQA) control. With advances in analytical technologies, high-resolution mass spectrometry (High-Resolution Mass Spectrometry, HRMS) has become a core tool for characterizing antibody subunit structures and molecular microheterogeneity, enabling refined analysis that extends from determining whether an antibody is structurally intact to identifying where specific structural differences occur.
Antibody Light- and Heavy-Chain Structure and Sources of Isoforms
Antibodies are assembled into a typical Y-shaped structure from two heavy chains and two light chains through disulfide bonds. During biopharmaceutical development and manufacturing, various forms of structural heterogeneity may arise due to post-translational modifications, differences in processing, or changes in the chemical environment. These changes often do not substantially alter the overall molecular mass profile of the antibody, but they may produce clear differences at the subunit level.
1. Structural Basis of Light- and Heavy-Chain Integrity
The integrity of light and heavy chains mainly depends on the correct polypeptide chain sequence and post-translational processing. Any truncation, degradation, or aberrant cleavage can result in molecular mass changes. For example, C-terminal lysine residues, incomplete signal peptide cleavage, or proteolysis can all cause small but detectable mass shifts. In high-resolution mass spectrometry, these changes can be captured as accurate mass differences at the ppm level.
2. Main Sources of Antibody Isoforms
Antibody isoforms mainly include glycosylation heterogeneity, N-terminal cyclization, such as pyroglutamate formation, deamidation, and interchain disulfide-bond rearrangement. These modifications usually do not disrupt the overall antibody structure, but they can alter physicochemical properties and functional characteristics. For example, differences in Fc-region glycosylation can affect antibody-dependent cellular cytotoxicity (ADCC) activity, whereas light-chain deamidation may influence antigen-binding affinity.
Principles of High-Resolution Mass Spectrometry for Assessing Antibody Light- and Heavy-Chain Integrity
High-resolution mass spectrometry determines whether a structure is intact by accurately measuring the experimental molecular mass of a protein or subunit and comparing it with the theoretical molecular mass. Its core advantage lies in the combination of high mass accuracy and isotopic resolving power, which enables the identification of extremely small structural changes.
1. Subunit Dissociation and Mass Spectrometric Detection Strategy
In antibody analysis, antibodies are typically reduced to generate light chains and heavy chains, which are then analyzed by liquid chromatography-mass spectrometry (LC-MS). Electrospray ionization (ESI) converts LC and HC into multiply charged ions, which are subsequently measured with high accuracy using high-resolution mass analyzers such as Orbitrap or Q-TOF instruments. Through deconvolution algorithms, the deconvoluted molecular masses of the light and heavy chains can be obtained.
2. Mass Deviation Analysis for Integrity Determination
Whether the light chain or heavy chain is intact is usually determined by comparing the deviation between theoretical mass and measured mass. In high-resolution MS, ppm-level mass accuracy can differentiate:
This level of precision upgrades antibody integrity analysis from a binary “presence-or-absence” assessment to structural-level confirmation.
3. Isotope Distribution and Signal Deconvolution
High-resolution mass spectrometry can also resolve isotopic envelopes and reconstruct the accurate mass of complex proteins by finely resolving signals from multiple charge states. This process is particularly important for distinguishing closely related isoforms, especially when glycosylation or minor modifications coexist.
High-Resolution Mass Spectrometry Strategies for Isoform Identification
Antibody isoforms usually manifest as small mass differences or differences in peak profiles. High-resolution MS can distinguish and quantify these species through multidimensional analytical strategies.
1. Glycosylation Isoform Analysis
Fc-region N-glycosylation is one of the most important sources of antibody heterogeneity. Different glycoforms, such as G0F, G1F, and G2F, introduce defined mass differences. High-resolution MS can directly detect glycoform distributions at the intact antibody or subunit level, enabling qualitative and relative quantitative analysis and thereby supporting evaluation of differences in antibody effector function.
2. Identification of Amino Acid Modification Isoforms
Modifications such as deamidation (+0.984 Da) and oxidation (+15.995 Da) can be accurately identified by high-resolution MS. These modifications often form groups of closely related microheterogeneous species. By combining LC separation with high-resolution detection, the proportions of different modification states can be characterized.
3. Analysis of Light-/Heavy-Chain Pairing Variants
Some antibodies may undergo mis-pairing during production, such as the association of a light chain with an incorrect heavy chain. High-resolution MS combined with reduced and non-reduced comparative analysis can identify abnormal pairing forms, thereby evaluating the correctness of antibody assembly.
Technical Challenges and Optimization Strategies
Although high-resolution MS shows strong performance in antibody analysis, it still faces certain challenges in practical applications.
1. Complex Charge States and Signal Overlap
Antibodies have relatively large molecular masses, and ESI generates complex multiply charged peak series, which may lead to signal overlap. By optimizing deconvolution algorithms and increasing resolving power, such as using high-resolution Orbitrap acquisition modes, analytical interpretation can be significantly improved.
2. Excessive Sample Heterogeneity
Antibodies naturally exhibit microheterogeneity, resulting in spectra with multi-peak distributions. Subunit analysis or multistage chromatographic separation can be used to reduce analytical complexity.
3. Difficulty in Interpretation Caused by Coexisting Modifications
When multiple PTMs (post-translational modifications) coexist, they generate complex mass combinations. Combining multidimensional mass spectrometry strategies, such as top-down and middle-down MS approaches, can improve structural interpretation capability.
High-resolution mass spectrometry provides unprecedented accuracy for the analysis of antibody light- and heavy-chain integrity and isoforms, making it possible to move biopharmaceutical structural characterization from macroscopic evaluation toward refined molecular-level analysis. Through subunit analysis, accurate mass measurement, and isoform identification strategies, researchers can comprehensively understand antibody structural heterogeneity and its functional consequences. MtoZ Biolabs continuously optimizes its high-resolution mass spectrometry analysis platform to provide high-precision structural characterization support for antibody drug development, quality control, and biosimilar evaluation, supporting higher standards in biopharmaceutical development and quality assessment.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
